GLP-1 Research Cycle Summary — May 20, 2026
This cycle tracked the GLP-1 drug boom across eight dimensions: pharma earnings/pipeline, Medicare policy, competitive landscape, medical devices, consumer behavior, and retail/apparel ripple effects.
Key Findings This Cycle
- Eli Lilly Q1 2026: $19.8B revenue (+56% YoY), 60.1% US GLP-1 market share, Foundayo oral GLP-1 approved April 1, triple-agonist retatrutide hit Phase 3 endpoints, guidance raised to $82–85B
- Novo Nordisk Q1 2026: Oral Wegovy crushed forecasts ($2.26B, strongest GLP-1 volume debut in US history), high-dose Wegovy showed 21% weight loss, CagriSema under FDA review, Amycretin Phase 3 began, but margins contracting and stock ~45% below peak
- Medicare GLP-1 Bridge: $50/month copay launching July 1, 2026, covering Foundayo/Wegovy/Zepbound for ~30M eligible beneficiaries — BALANCE permanent model to follow in 2027
- Medicare Cost-Neutrality (JAMA Network Open): MFN pricing at $245/month ($195 net) brings coverage close to breakeven — net ~$18B over 10 years vs. $48B at prior pricing
- Trump Lilly Stock Purchases: President purchased up to $680K in LLY stock while administration advanced pro-GLP-1 policies — potential political/regulatory headline risk
- Kailera Therapeutics IPO: First pure-play GLP-1 public challenger, raised $625M at $16/share, lead candidate ribupatide in Phase 3
- ForePass Endoscopic Device: Published in Gut, outperformed semaglutide 8:1 in preclinical weight control — potential device-based disruptor to GLP-1 drugs
- Restaurant Industry Impact: 12% of US adults on GLP-1s, 8% fast-food spending cut within 6 months, chains adapting with smaller portions and protein-forward menus
- Apparel/Retail Ripple Effects: GLP-1 users spend 40%+ more on clothing; Wells Fargo upgrades intimates/denim/dresses, downgrades Nike and Deckers on footwear underperformance
Open Questions for Future Cycles
- Wegovy alcohol addiction trial results and market sizing
- Supreme Court Medicare price negotiations ruling impact on GLP-1 timeline
- NIH hedonic eating study — broader CNS/addiction implications
- Retatrutide multi-indication (osteoarthritis pain) data and TAM expansion
- Viking Therapeutics VK2735 Phase 3 progress and takeover potential
- French regulators fining Novo/Lilly ~€2M — broader EU regulatory landscape
- Denecimig (Mim8) hemophilia approval and non-GLP-1 diversification for Novo